COMMUNIQUÉS West-GlobeNewswire

Pharming Group reports first quarter 2025 financial results and provides business update
08/05/2025
First quarter 2025 total revenues increased by 42% to US$79.1 million, compared to the first quarter 2024 RUCONEST® revenue increased by 49% to US$68.6 million, compared to the first quarter 2024, reflecting continued [...]
Genespire announces oral presentation at the ASGCT Annual Meeting detailing preclinical insights into dosing for first-in-human in vivo liver-directed ISLV gene therapy for MMA
08/05/2025
Milan, ITALY – 8 May 2025 – Genespire, a biotechnology company developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases, today announces an upcoming oral presentation showcasing [...]
Vancouver-Based Delfi Medical Innovations Takes Blood Flow Restriction Technology to New Heights — Literally
08/05/2025
VANCOUVER, British Columbia, May 07, 2025 (GLOBE NEWSWIRE) -- Delfi Medical Innovations Inc., a global leader in blood flow restriction (BFR) technology based in Vancouver, is proud to announce that its equipment has [...]
Ashvattha Therapeutics to Present Positive Phase 2 Results for Subcutaneous Migaldendranib in Retinal Vascular Disease at ARVO
07/05/2025
Subcutaneous administration generally safe and well-tolerated across multiple doses >80% reduction in anti-VEGF intravitreal injection burden in wet AMD and DME study eyes and >75% total reduction in fellow eyes [...]
Pasithea Therapeutics Announces Closing of $5 Million Public Offering
07/05/2025
Additional Gross Proceeds of Approximately $1.3 Million Received Upon Exercise of Certain Warrants Issued in the Public Offering MIAMI, May 07, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics, Corp. (“Pasithea,” or the “ [...]
Ultragenyx to Participate at Bank of America’s 2025 Healthcare Conference
07/05/2025
NOVATO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra- [...]
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07/05/2025
CLEVELAND, May 07, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in [...]
Viemed Healthcare Announces First Quarter 2025 Financial Results
07/05/2025
LAFAYETTE, La., May 07, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced [...]
Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update
07/05/2025
Total Revenues in the first quarter of 2025 reached $132.8 million, compared to $36.9 million in the same period last year, representing a 260% increase Product Revenues in the first in the first quarter of 2025 reached [...]
Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update
07/05/2025
Total Revenues in the first quarter of 2025 reached $132.8 million, compared to $36.9 million in the same period last year, representing a 260% increase Product Revenues in the first in the first quarter of 2025 reached [...]
Lifeward to Report First Quarter 2025 Financial Results on May 15, 2025
07/05/2025
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of [...]
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
07/05/2025
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 07 mai 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 Date Nombre total d’actions composant le [...]
Monthly information on share capital and company voting rights
07/05/2025
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, May 07, 2025 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the capital [...]
Nyxoah to Release First Quarter 2025 Financial Results on May 14, 2025
07/05/2025
Nyxoah to Release First Quarter 2025 Financial Results on May 14, 2025 Mont-Saint-Guibert, Belgium – Wednesday May 7, 2025, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company [...]
Nyxoah Publiera ses Résultats Financiers du Premier Trimestre 2025 le 14 Mai 2025
07/05/2025
Nyxoah Publiera ses Résultats Financiers du Premier Trimestre 2025 le 14 Mai 2025 Mont-Saint-Guibert, Belgique – 7 mai 2025, 22h30 CET / 16h30 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la « Société [...]
Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology
07/05/2025
Study suggests that utilizing RiskScore drives breast cancer screening tailored to individual risk SALT LAKE CITY, May 07, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostic [...]
STERIS Declares Dividend of $0.57 per share
07/05/2025
DUBLIN, IRELAND, May 07, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.57 per share. The dividend is [...]
DLH Reports Fiscal 2025 Second Quarter Results
07/05/2025
Solid Cash Flow and Debt Reduction Strengthen Financial Outlook as Bid Activity Accelerates ATLANTA, May 07, 2025 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of [...]
Korro Reports First Quarter 2025 Financial Results and Provides Business Updates
07/05/2025
— Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD) on track for the second half of 2025 — Streamlining operations and focusing on delivering potential value [...]

Pages